Tikva Allocell
Singapore-headquartered cell therapy company founded in 2023 developing off-the-shelf allogeneic T-cell therapies; its lead program TAVST01 is a B7-H3-targeted EBV-specific T-cell therapy built on the ALLO SerpinB9 EBVST platform licensed exclusively from Baylor College of Medicine, in IND-enabling development ahead of planned Phase 1 trials in Singapore and the United States.
Headquarters
Singapore
Year Founded
2023
Founders
Not disclosed
Country
Singapore
Financial Information
Funding Stage
Series A
Recent Funding
$8M
Funding By
Kantharos Capital
Core Technology
ALLO SerpinB9 EBVST platform (allogeneic EBV-specific T cells) with B7-H3 targeting
Product Type
Cell Therapy
Pipeline Stage (Very Important)
Regulatory Status
- IND Filed: No
- FDA/EMA Status: N/A
- Clinical Trial Registration: Planned Phase 1 in Singapore and the US following IND submission
- Patents / IP Status: Exclusive license from Baylor College of Medicine
Partnerships
Pharma Collaborations
None disclosed
Academic / Hospital Tie-ups
Baylor College of Medicine (exclusive technology license)
CRO/CDMO Partnerships
None disclosed
Market & Differentiation
SerpinB9 engineering resists immune rejection, enabling off-the-shelf dosing for solid tumors